February 08, 2013 -- AXIS Clinicals Group, a leading global clinical research organization (CRO), has announced the appointment of Dr Yati Chugh as the Chief Executive Officer of AXIS Clinicals Limited. Dr Chugh assumes the responsibility for overall activities of AXIS Clinicals Group companies with presence in India, Thailand and Mexico. Under his leadership and guidance, AXIS Clinicals team will ensure that services are offered to partners with dedication, commitment, quality and performance.
Dr Chugh brings over two decades of experience in conducting pre-clinical, Bioequivalence/Bioavailability (BA/BE) studies and clinical research. He has extensive experience in areas of CNS, CVS, drug metabolism/pharmacokinetics and clinical pharmacology.
“As AXIS Clinicals is one of the leading CROs of the country, that provides clinical studies on both male and female healthy patient population in virtually all therapeutic areas, I am looking forward to our continued leadership in delivering the AXIS advantage of timely deliveries, accuracy and quality in accordance to global standards to our clients and partners,” Dr Yati Chugh, CEO said. “Our fundamental focus is to provide our customers a complete clinical research portfolio under one roof that will help them achieve the competitive advantage needed in staying ahead,” he added.
Dr Chugh holds a doctorate degree from PGIMER, Chandigarh, and has published about 45 scientific papers in reputed national and international peer-reviewed journals. He has completed his Master’s and Ph.D in pharmacology from PGIMER and graduated in B. Pharm from Department of Pharmaceutical Sciences, Punjab University, Chandigarh. He has about 25 patents to his credit and is a member of all the major international bodies of pharmacology and is a reviewer in major journals of pharmacology.
Prior to joining AXIS Clinicals, Dr Chugh was heading Lotus Labs as Managing Director. He has been associated with several reputed biopharmaceutical companies like Wockhardt, Intas Pharmaceuticals, Torrent Pharmaceuticals Limited for over two decades.